Benjamin Edwards Inc. Increases Position in Pfizer Inc. $PFE

Benjamin Edwards Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 17.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 237,703 shares of the biopharmaceutical company’s stock after acquiring an additional 35,243 shares during the quarter. Benjamin Edwards Inc.’s holdings in Pfizer were worth $5,724,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the business. Brighton Jones LLC increased its holdings in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. United Bank grew its position in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares in the last quarter. Sei Investments Co. increased its holdings in shares of Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC increased its holdings in shares of Pfizer by 45.3% in the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. JPMorgan Chase & Co. dropped their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the company from $32.00 to $28.00 in a report on Monday, July 6th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $28.28.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

Pfizer Trading Down 0.0%

Shares of NYSE:PFE opened at $27.95 on Monday. The company has a market cap of $159.31 billion, a PE ratio of 36.78 and a beta of 0.34. The company’s 50-day moving average price is $25.55 and its 200 day moving average price is $26.30. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.